Drugs / adipose-derived regenerative cells
adipose-derived regenerative cells
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03269409 | Nov 2017 → Jun 2021 | osteonecrosis | Mayo Clinic | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02904824 | Jul 2012 → Sep 2014 | — | Hospital General Universitario Gregorio Marañon | Completed | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT02866565 | Jun 2023 → Sep 2026 overdue | ulcer of lower limbs | Assistance Publique Hopitaux De Marseille | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT03776721 | Dec 2018 → Jun 2021 | lymphedema | Odense University Hospital | Completed | Missed primary |
| Phase 2 | NCT07355530 | Jan 2018 → Mar 2021 | — | Odense University Hospital | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02529865 | Jul 2015 → Mar 2019 | female stress incontinence | Nagoya University | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT03503305 | Nov 2018 → Mar 2026 overdue | osteoarthritis | InGeneron, Inc. | Active not recruiting | No outcome recorded |
| — | NCT02918136 | Dec 2016 → Jul 2018 | rotator cuff syndrome | InGeneron, Inc. | Completed | No outcome recorded |
| — | NCT02987101 | Nov 2016 → Jun 2018 | ulcer of lower limbs | Odense University Hospital | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2025-07-23 | InGeneron, Inc. | Results InGeneron Publishes Landmark Study Demonstrating Structural Tendon Regeneration with Autologous Cell Therapy System ingeneron.com ↗
In Vivo Regeneration: Proved functional tissue regeneration in animal models with histology and biomechanical testing, as shown in this newly published study – Schmitz et al., Int. J. Mol. Sci. 2025;26:6800 |
| 2023-11-13 | InGeneron, Inc. | Results InGeneron Reports Positive Long-Term Results for its Cell Therapy in Partial-Thickness Rotator Cuff Tears ingeneron.com ↗
This long-term follow-up study, conducted over 41 months (3.4 years) post-treatment, showed that ADRCs were not only safe, but also more effective than corticosteroid injections for improving shoulder function and reducing pain in the treated patients. |
| 2023-01-06 | InGeneron, Inc. | Results New Study Reports Broad Applicability of InGeneron’s Regenerative Cell Therapy System Across Patient Groups ingeneron.com ↗ |
| 2021-07-23 | InGeneron, Inc. | Results InGeneron Reports First-In-Human Microscopic Evidence of Adult Tendon Regeneration Following Autologous Stem Cell Treatment ingeneron.com ↗
The analysis strongly indicates regenerative healing of the tendon, resulting from transformation of UA-ADRCs into new tendon tissue. |
| 2020-04-07 | InGeneron, Inc. | Results InGeneron Announces Publication of Rotator Cuff Feasibility Study ingeneron.com ↗
FDA-Approved Randomized Controlled Feasibility Study Finds InGeneron’s Regenerative Cell Therapy to Significantly Reduce Pain and Improve Shoulder Function Over Corticosteroid Injection to Address Symptomatic Partial-Thickness Rotator Cuff Tears |
| 2019-10-31 | InGeneron, Inc. | Results InGeneron Announces Publication of Preclinical Results for its Cell Therapy in Chronic Ischemic Heart Failure ingeneron.com ↗
Specifically, the study demonstrates that InGeneron’s fresh, uncultured, autologous adipose-derived regenerative cells (UA-ADRCs) – isolated and administered at the point of care – provide a significant improvement of cardiac circulatory parameters in chronic ischemic heart failure. |
| 2019-03-21 | InGeneron, Inc. | Results InGeneron Announces Publication of Results from First-in-Human Case Report of its Cell Therapy in Bone Regeneration ingeneron.com ↗
A comparison of histological data, gathered from tissue biopsies on each side of the patient’s jaw six and 34 weeks after the procedure, indicates that the ADRC treatment is safe and well-tolerated and, additionally, that it leads to better and faster bone regeneration compared to the site treated with PRGF-2 and a scaffold only. |
| 2017-09-18 | InGeneron, Inc. | Results InGeneron Announces Publication of Positive Results from Investigator-Initiated Wound Healing Case Series Using Company’s Regenerative Cell Technology ingeneron.com ↗
Within 10 to 25 weeks, 11 out of the 16 patients showed complete wound closure. |
| 2016-11-21 | InGeneron, Inc. | Results InGeneron Announces Presentation of Results from Investigator Initiated Case Series of its Regenerative Cell Therapy in Chronic Back Pain at IFATS ingeneron.com ↗ |
All press releases naming this drug 9 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | adipose-derived regenerative cells | “Open-label, Multi-center, Single Arm Study to Evaluate the Efficacy and Safety of Periurethral Injection of Autologous Adipose Derived Regenerative Cells (ADRCs) for the...” NCT02529865 ↗9“Open-label, Multi-center, Single Arm Study to Evaluate the Efficacy and Safety of Periurethral Injection of Autologous Adipose Derived Regenerative Cells (ADRCs) for the...” NCT02529865 ↗ “The focus of this study is to investigate the therapeutic benefit of autologous adipose-derived regenerative cells in patients with wrist arthritis.” NCT03503305 ↗ “using adipose-derived regenerative cells (ADRCs) and lipotransfer in alleviating BCRL through regeneration of lymphatic tissue” PMID 39591365 ↗ Feb 2024 |
| Known as | ADRC | “Subjects in this arm will have Adipose Derived Regenerative Cells (ADRC)harvested through autologous liposuction and processed outside the body using The Celution 800/GP System...” NCT03269409 ↗1“ADRC, adipose derived regenerative cells” NCT02904824 ↗ |
| Known as | ADRCs | “Open-label, Multi-center, Single Arm Study to Evaluate the Efficacy and Safety of Periurethral Injection of Autologous Adipose Derived Regenerative Cells (ADRCs) for the...” NCT02529865 ↗4“Subjects in the treated group will receive an Adipose derived regenerative cells (ADRCs) injection into the wrist using a fluoroscopic-guided injection .” NCT03503305 ↗ “using adipose-derived regenerative cells (ADRCs) and lipotransfer in alleviating BCRL through regeneration of lymphatic tissue” PMID 39591365 ↗ Feb 2024 “Early data suggest that enriching fat grafts with adipose-derived regenerative cells (ADRCs) promote angiogenesis” PMID 29760737 ↗ Apr 2018 “adipose-derived regenerative cells (ADRCs)” NCT02866565 ↗ |
| Modality | Cell therapy | “periurethral injection of autologous regenerative cells from adipose tissue” PMID 28946874 ↗ Sep 2017 |
| Route | Other | “periurethral injection of autologous ADRCs and adipose tissue” NCT02529865 ↗ |